risedronic acid has been researched along with Breast Neoplasms in 39 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin." | 7.80 | Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Among patients with mild or severe osteopenia or osteoporosis treated with A + R, 12 months LS or HP BMD variations were configured regardless of age group." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes." | 5.16 | Lipid profiles within the SABRE trial of anastrozole with and without risedronate. ( Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C, 2012) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "Fifty-three white women, aged 36 to 55 years, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use." | 5.08 | Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. ( Balena, R; Bremond, A; Confravreux, E; Delmas, PD; Hardouin, C; Hardy, P, 1997) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin." | 3.80 | Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Our goal was to examine prevention of breast cancer-related bone loss in this cohort." | 2.73 | Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. ( Bhattacharya, R; Brufsky, A; Greenspan, SL; Lembersky, BC; Perera, S; Sereika, SM; Vogel, VG; Vujevich, KT, 2008) |
| "The use of endocrine therapy in breast cancer represents one of the earliest molecular targeting strategies used in cancer treatment." | 2.46 | Challenges in clinical patient management. ( Aapro, MS, 2010) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Among patients with mild or severe osteopenia or osteoporosis treated with A + R, 12 months LS or HP BMD variations were configured regardless of age group." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The modalities of recognition of breast tumors by Vγ9Vδ2 T cells in N-BP-treated animals were also examined." | 1.38 | In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. ( Benzaïd, I; Bonnelye, E; Clézardin, P; Mönkkönen, H; Mönkkönen, J, 2012) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "A total of 696 women with stage I-III breast cancer were included." | 1.36 | Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System. ( Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K, 2010) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| " We next showed that risedronate given at a low dosage in animals bearing human B02-GFP breast tumors reduced osteolysis by inhibiting bone resorption, whereas therapy with higher doses also inhibited skeletal tumor burden." | 1.35 | Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. ( Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ, 2008) |
| "Subjects were 17 postmenopausal breast cancer patients (mean age, 63." | 1.34 | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007) |
| "Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia." | 1.29 | Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 22 (56.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sestak, I | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Coleman, RE | 1 |
| Cuzick, J | 2 |
| Eastell, R | 3 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Ben-Aharon, I | 1 |
| Vidal, L | 1 |
| Rizel, S | 1 |
| Yerushalmi, R | 1 |
| Shpilberg, O | 1 |
| Sulkes, A | 1 |
| Stemmer, SM | 1 |
| Mansouri, M | 1 |
| Mirzaei, SA | 1 |
| Lage, H | 1 |
| Mousavi, SS | 1 |
| Elahian, F | 1 |
| Ebert, R | 1 |
| Meissner-Weigl, J | 1 |
| Zeck, S | 1 |
| Määttä, J | 1 |
| Auriola, S | 2 |
| Coimbra de Sousa, S | 1 |
| Mentrup, B | 1 |
| Graser, S | 1 |
| Rachner, TD | 1 |
| Hofbauer, LC | 1 |
| Jakob, F | 1 |
| Dueck, AC | 1 |
| Singh, J | 1 |
| Atherton, P | 1 |
| Liu, H | 1 |
| Novotny, P | 1 |
| Hines, S | 1 |
| Loprinzi, CL | 2 |
| Perez, EA | 2 |
| Tan, A | 1 |
| Burger, K | 1 |
| Zhao, X | 1 |
| Diekmann, B | 1 |
| Sloan, JA | 2 |
| Greenspan, SL | 7 |
| Vujevich, KT | 5 |
| Brufsky, A | 5 |
| Lembersky, BC | 3 |
| van Londen, GJ | 5 |
| Jankowitz, RC | 2 |
| Puhalla, SL | 2 |
| Rastogi, P | 3 |
| Perera, S | 6 |
| Zlatev, HP | 1 |
| Mönkkönen, J | 2 |
| Määttä, JA | 1 |
| Prasad, C | 1 |
| Sereika, SM | 4 |
| Bhattacharya, R | 3 |
| Fournier, PG | 2 |
| Daubiné, F | 1 |
| Lundy, MW | 1 |
| Rogers, MJ | 1 |
| Ebetino, FH | 2 |
| Clézardin, P | 3 |
| Hines, SL | 1 |
| Mincey, BA | 1 |
| Thomas, SP | 1 |
| Chottiner, E | 1 |
| Carlson, MD | 1 |
| Atherton, PJ | 1 |
| Salim, M | 1 |
| Bivi, N | 1 |
| Romanello, M | 1 |
| Harrison, R | 1 |
| Clarke, I | 1 |
| Hoyle, DC | 1 |
| Moro, L | 1 |
| Ortolani, F | 1 |
| Bonetti, A | 1 |
| Quadrifoglio, F | 1 |
| Tell, G | 1 |
| Delneri, D | 1 |
| Waltman, NL | 1 |
| Twiss, JJ | 1 |
| Ott, CD | 1 |
| Gross, GJ | 1 |
| Lindsey, AM | 1 |
| Moore, TE | 1 |
| Berg, K | 1 |
| Kupzyk, K | 1 |
| Van Poznak, C | 2 |
| Hannon, RA | 1 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 2 |
| Barlow, D | 1 |
| Makris, A | 2 |
| Markopoulos, C | 2 |
| Tzoracoleftherakis, E | 2 |
| Polychronis, A | 1 |
| Venizelos, B | 2 |
| Dafni, U | 1 |
| Xepapadakis, G | 2 |
| Papadiamantis, J | 1 |
| Zobolas, V | 2 |
| Misitzis, J | 2 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 2 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 2 |
| Stresing, V | 1 |
| Aapro, MS | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Vujevich, K | 1 |
| Lembersky, B | 1 |
| Vogel, V | 1 |
| Nahleh, Z | 1 |
| Abrams, J | 1 |
| Bhargaval, A | 1 |
| Nirmal, K | 1 |
| Graff, JJ | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Barlow, DH | 1 |
| Benzaïd, I | 1 |
| Mönkkönen, H | 1 |
| Bonnelye, E | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Verdijk, R | 1 |
| Franke, HR | 1 |
| Wolbers, F | 1 |
| Vermes, I | 1 |
| Bhattacharya, RK | 1 |
| Vogel, VG | 2 |
| Malden, NJ | 1 |
| Pai, AY | 1 |
| Yonehara, Y | 1 |
| Iwamoto, I | 1 |
| Kosha, S | 1 |
| Rai, Y | 1 |
| Sagara, Y | 1 |
| Douchi, T | 1 |
| Suyama, K | 1 |
| Noguchi, Y | 1 |
| Tanaka, T | 1 |
| Yoshida, T | 1 |
| Shibata, T | 1 |
| Saito, Y | 1 |
| Tatsuno, I | 1 |
| Sasaki, A | 1 |
| Boyce, BF | 1 |
| Story, B | 1 |
| Wright, KR | 1 |
| Chapman, M | 1 |
| Boyce, R | 1 |
| Mundy, GR | 1 |
| Yoneda, T | 1 |
| Delmas, PD | 1 |
| Balena, R | 1 |
| Confravreux, E | 1 |
| Hardouin, C | 1 |
| Hardy, P | 1 |
| Bremond, A | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Crandall, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma[NCT00054418] | Phase 3 | 216 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)[NCT00118508] | 87 participants (Actual) | Interventional | 2003-05-31 | Completed | |||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
5 reviews available for risedronic acid and Breast Neoplasms
| Article | Year |
|---|---|
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2013 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etid | 2010 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
15 trials available for risedronic acid and Breast Neoplasms
| Article | Year |
|---|---|
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2015 |
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Density | 2015 |
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Topics: Aromatase Inhibitors; Bone and Bones; Bone Density; Breast Neoplasms; Cancellous Bone; Cancer Surviv | 2016 |
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Aci | 2008 |
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neo | 2009 |
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone | 2010 |
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Double-Blind | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
Topics: Adipose Tissue; Aromatase Inhibitors; Body Composition; Body Mass Index; Bone Density; Breast Neopla | 2011 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Etidron | 2007 |
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Die | 2008 |
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Topics: Adult; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Do | 1997 |
19 other studies available for risedronic acid and Breast Neoplasms
| Article | Year |
|---|---|
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tum | 2014 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, | 2014 |
Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells.
Topics: Breast Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Endocytosis; Female; Humans; Imidazoles | 2016 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combinati | 2008 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Ce | 2009 |
How do bisphosphonates inhibit bone metastasis in vivo?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell L | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Aci | 2010 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Prolife | 2012 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cycl | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density Conservation Agents; B | 2007 |
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid | 1995 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |